Citius Oncology, Inc. (CTOR) Research

Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.

Market snapshot

Symbol
CTOR
Price
$0.67
Day change
+1.44%
Market cap
$62.3M
P/E ratio
-1.58x
52-week range
0.491-6.19
Sector
Healthcare
Industry
Drug Manufacturers - General
Next earnings
in 2 months
Analyst price target
$6.00

Peer companies

  • Actuate Therapeutics Inc (ACTU)
  • Applied Therapeutics, Inc. (APLT)
  • Fate Therapeutics, Inc. (FATE)
  • Forte Biosciences, Inc. (FBRX)
  • LENSAR, Inc. (LNSR)
  • Seres Therapeutics, Inc. (MCRB)
  • Owlet, Inc. (OWLT)
  • Scilex Holding Company (SCLX)

Recent insider activity

  • HOLUBIAK MYRON Z — A-Award (850000 shares) on 2025-09-19
  • HOLUBIAK MYRON Z — A-Award (100000 shares) on 2025-09-19
  • Smith Robert Joseph — A-Award (300000 shares) on 2025-09-19
  • Mazur Leonard L — A-Award (1700000 shares) on 2025-09-19
  • Webb Carol — A-Award (300000 shares) on 2025-09-19

Open Citius Oncology, Inc. (CTOR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.